Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
CoreCard Corporation CCRD: This technology solutions and processing services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
CoreCard’s shares gained 44.9% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
CoreCard Corporation price | CoreCard Corporation Quote
Entrada Therapeutics, Inc. TRDA: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
Entrada’s shares gained 8.8% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. NRXP: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx’s shares gained 11.8% over the past month compared with the S&P 500’s decline of 0.7%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report
Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report
CoreCard Corporation (CCRD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。